In comparison to NALM6 cancer cells, both CAR designs could respond with equal or higher intensity (Fig. 4b), dynamic range (Supplementary Fig. 16, 17), and responsiveness (Supplementary Fig. 19) to CD19+ SCASA yeast. The gene discussed is CD19; the disease is cancer.